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Summary 
Mutations in the APC gene are responsible for various 
familial and sporadic colorectal cancers. Min mice 
carry a dominant mutation in the homolog of the Apc 
gene and develop multiple adenomas throughout their 
small and large intestine. Quantitative trait loci studies 
have identified a locus, Moml, which maps to the dis- 
tal region of chromosome 4, that dramatically modifies 
Min-induced tumor number. We report here the identi- 
fication of a candidate gene for Morn/. The gene for 
secretory type II phospholipase A2 (Pla2s) maps to the 
same region that contains Morn1 and displays 100% 
concordance between allele type and tumor suscepti- 
bility. Expression and sequence analysis revealed that 
Morn1 susceptible strains are most likely null for Pla2s 
activity. Our results indicate that Pla2s acts as a novel 
gene that modifies polyp number by altering the cellu- 
lar microenvironment within the intestinal crypt. 
Introduction 
Mutations of the human adenomatous polyposis coil (APC) 
gene are responsible for both sporadic and familial colo- 
rectal cancers (Nishisho et al., 1991; Groden et al., 1991). 
Germline mutations of APC are found in inherited familial 
cancers such as Gardner's syndrome, attenuated APC, 
and familial adenomatous polyposis (FAP) (N ishisho et al., 
1991; Spirio et al., 1992). FAP is an autosomal dominant 
inherited isease predisposing the patient o colon cancer. 
Patients inheriting a single mutant allele of APC develop 
hundreds to thousands of adenomatous polyps in the sec- 
ond to third decades of life that, if left untreated, progress 
to malignant carcinomas (Hamilton, 1989). Genetic link- 
age analysis localized APC to human chromosome 5q21- 
q22, a region frequently associated with allelic loss of the 
wild-type 5q allele (Bodmer et al., 1987; Leppert et al., 
1987; Kinzler et al., 1991). Mutations in APC are also impli- 
cated in extracolonic tumors such as gastric and small 
intestinal polyps, osteomas, sarcomas, and desmoidal tu- 
mors (Leppert et al., 1990; Spirio et al., 1992; Klemmer 
et al., 1987). 
A mutant mouse strain is being used as a model to un- 
derstand better the genetic elements influencing the pro- 
gression of colorectal tumorigenesis. The multiple intesti- 
nal neoplasia (Min) strain, established from an ethylni- 
trosourea-treated C57BL/6J (B6) male mouse, carries a 
dominant mutation (Moser et al., 1990). Mice heterozy- 
gous for the Min mutation develop numerous adenomas 
throughout the small and large intestinal tract. The ob- 
served phenotype in Min mice closely resembles the clini- 
cal features observed in patients with FAP. Genetic linkage 
analysis localized the Min mutation to mouse chromosome 
18, in a region known to contain the Apc gene, the murine 
homolog of the human APC gene (Luongo et al., 1993). 
Further studies revealed that the Min mutation (hereafter 
called Apc Mjn) results from a nonsense mutation in exon 
15 of the Apc gene; the same type of mutation is frequently 
found in human FAP kindreds (Suet al., 1992). 
The genetic and phenotypic similarities observed be- 
tween Min mice and FAP patients suggest that the Min 
mouse model is a powerful system to study this human 
disease. Examination of FAP kindreds demonstrate that 
family members inheriting the same APC mutation may 
differ dramatically in tumor burden (Leppert et al., 1990). 
Although environmental factors may be partially responsi- 
ble, modifier genes have been proposed to account for 
some of this variability (Paul et al., 1993; Giardiello et al., 
1994). The use of a genetically defined system, such as 
the Min mouse model, facilitates the identification of these 
modifier loci. Min mice differ greatly in the number of intes- 
tinal tumors, depending on their genetic background 
(Moser et al., 1992; Dietrich et al., 1993). B6 mice heterozy- 
gous for the Apc Mj" mutation exhibit an average of 28.5 
polyps throughout heir intestines, while their F1 progeny 
produced from crosses to either AKR/J (AKR), MNMyJ 
(MA), or Mus castaneus (CAST) mice exhibit an average 
of only 5.8, 5.7, and 3.0 polyps, respectively (Moser et al., 
1992; Dietrich et al., 1993). These studies indicate that at 
least one dominantly acting allele is modifying the influ- 
ence of the Apc =i" mutation on polyp susceptibility. Quanti- 
tative trait loci (QTL) mapping subsequently identified a 
locus, Morn1 (for modifier of Min 1), in the distal region of 
chromosome 4 between D4Mit16 and D4Mit13. Morn1 is 
estimated to account for -50% of the genetic variation 
in adenoma number in both AKR and MA backcrosses 
as compared with B6 (Dietrich et al., 1993). Interestingly, 
Morn 1 also resides in a region of synteny with human chro- 
mosome lp35, a region frequently associated with loss 
of heterozygosity in neuroblastomas and colon cancer 
(Martinsson et al., 1989; Leister et al., 1990). 
It has not yet been determined whether the Morn1 gene 
product acts autonomously or noncell autonomously with 
respect to the tumor cell lineage (Moser et al., 1993). Poly- 
merase chain reaction (PCR) analysis has shown that 
100% of spontaneous Min-induced intestinal adenomas 
have lost their wild-type Apc allele, suggesting that Apc 
acts as a classical tumor suppressor gene (Levy et al., 
1994; Luongo et al., 1994). Immunocytochemical nalysis 
of these adenomas has demonstrated that the intestinal 
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lesions consist of a mixture of differentiated enterocytes, 
enteroendocrine, goblet, and Paneth cells; these findings 
are similar to what is observed in human adenomatous 
polyps (Moser et al., 1992; Kirkland, 1988). The presence 
of multiple lineages in these adenomas suggests that a 
multipotent stem cell population located at the base of 
intestinal crypts is the site of initiation for Apc~J"-induced 
tumorigenesis. Therefore, any modifier gene expressed 
in the crypt microenvironment would have a potential role 
in altering tumor progression. 
We report here the genetic mapping, expression, and 
sequence analysis of a candidate gene for the Moml lo- 
cus. The present data are consistent with the hypothesis 
that Moml is encoded by the secreted form of type II non- 
pancreatic phospholipase A2 (Pla2s). Pla2s is a low molec- 
ular mass (14 KDa) phospholipase belonging to a diverse 
family of enzymes that hydrolyze the sn-2 fatty acyl ester 
bond of phosphoglycerides toproduce free fatty acids and 
lysophospholipids (reviewed by Kudo et al., 1993; Dennis 
1994). Pla2s is one of the enzymes involved in the produc- 
tion of arachidonic acid, which is the rate-limiting substrate 
for the production of leukotrienes and prostaglandins (re- 
viewed by Glaser et al., 1993). Pla2s has also been impli- 
cated in the pathophysiology of acute pancreatitis, rheu- 
matoid arthritis, and asthma (Kaiser et al., 1990). High 
levels of Pla2s expression have been detected in rat and 
murine small intestine; the Pla2s enzyme has been local- 
ized to Paneth cells at the base of the crypts of Lieberkuhn 
(Mulherkar et al., 1991, 1993). Expression of this enzyme 
coincides with the appearance of mature Paneth cells, 
suggesting the presence of Pla2s during the establishment 
and maintenance of the villus epithelium (Bry et al., 1994). 
To study further the role of Pla2s in development and 
pathogenesis, we determined its chromosome location in 
the mouse. We initially mapped Pla2s between the 
D4Mit16 and D4Mit13 loci, which is the same region of 
mouse chromosome 4that contains the Morn 1 locus. Anal- 
ysis of the Pla2s gene from inbred mouse strains revealed 
a 100% concordance between allele type and polyp num- 
ber. Based on our mapping of Pla2s to distal chromosome 
4, the correlation between specific Pla2s alleles and polyp 
susceptibility, and the expression of Pla2s at the tumor 
initiation site, we propose that Morn1 encodes the gene 
for Pla2s. Hence, Pla2s is a genetically defined locus that 
can modify or influence the number of intestinal tumors 
resulting from a mutation in the Apc gene. 
compared with known gene and microsatellite markers 
that scan the entire mouse genome (A. M. B. and 
L. D. S., unpublished ata). The segregation analysis re- 
vealed that the Pla2s gene resides on mouse chromosome 
4. The specific location of P/a2s was determined by min- 
imizing the number of multiple recombinations along the 
chromosome (Figure 1A). The results positioned Pla2s be- 
tween D4Mit148 and D4Mit13 in the distal region of chro- 
mosome 4 (Figure 1B). The order of the loci and the ratio 
of the number of recombinants to the total number of N2 
offspring examined are centromere-D4Mit16 (19 of 183)- 
D4Mit148 (1 of 170)-Pla2s (8 of 172)-D4Mit13-telomere. 
The genetic distance between loci in centiMorgans (_.+ 
SEM) are centromere-D4Mit16 (10.4 _+ 2.2 cM)-D4Mit148 
(0.6 _+ 0.6 cM)-Pla2s (4.6 _.+ 1.6 cM)-D4Mit13-telomere. 
The localization of Pla2s to the region between D4Mit148 
and D4Mit13 coupled with the observation that Pla2s is 
expressed at high levels in the murine small and large 
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Results 
Chromosomal Location of the Murine Pla2s Gene 
An interspecific backcross mapping panel was used to 
localize Pla2s in the mouse. Genomic DNAs from AEJ/ 
Gn and Mus spretus parental control mice were digested 
with 14 restriction endonucleases and analyzed by South- 
ern blot hybridization using the Pla2s probe. An informa- 
tive restriction fragment length polymorphism (RFLP) was 
detected with BamHI (see Experimental Procedures). The 
segregation pattern of the Pla2s gene was followed in 195 
N2 progeny. The allele distribution pattern of Pla2s was 
Figure 1. The Pla2s Gene Maps to Mouse Chromosome 4 
(A) Haplotype analysis of the loci mapped is shown. The loci mapped 
are listed to the left, with the most proximal locus listed first. A total 
of 167 N2 progeny were typed for all markers. Each column represents 
the chromosome inherited from the F1 parent. Closed squares repre- 
sent the AEJ/Gn allele. Open squares represent the M. spretus allele. 
The number of N2 progeny carrying each type of chromosome islisted 
below each column. 
(B) Loci mapped in the interspecific backcross (left). Distances be- 
tween the loci (in centiMorgans) are listed to the left. The interspecific 
backcross map is aligned (broken line) with the composite map of 
mouse chromosome 4 (right) (Lyon and Kirby, 1995). The predicted 
location of Morn1 is shown by the double-headed arrow (Dietrich et 
al., 1993). Underlined loci have their human genome localization listed 
to the right. 
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intestine (Mulherkar et al., 1991, 1993) suggested Pla2s 
as a candidate for the Morn1 locus. 
Comparison of Pla2s Expression Levels between 
Moml-Resiatant and Moml-Susceptible Strains 
B6 mice carrying the Apc M~" mutation typically have an 
average of 28.5 _+ 7.9 tumors (Moser et al., 1990). How- 
ever, when B6 ApcM/n/+ mice were crossed with AKR, MA, 
or CAST mice, the F1 progeny inheriting the Apc Mj" allele 
demonstrated a decrease in tumor burden (an average of 
5.8 + 4.3, 5.7 _ 4.0, and 3.0 -4- 1.8 tumors, respectively) 
(Moser et al., 1992; Dietrich et al., 1993). QTL mapping 
suggested that the strains demonstrating resistance to tu- 
mor formation have a dominant modifier gene responsible 
for suppressing the Min phenotype (Dietrich et al., 1993). 
Thus, B6 mice are considered susceptible to multiple in- 
testinal adenomas and carry a Morn18 allele, while AKR, 
MA, and CAST mice are resistant to multiple intestinal 
adenomas and carryaMoml rallele. Therefore, we hypoth- 
esized that if Pla2s was involved, the level or quality of 
mRNA would differ between Moml  ~ and Morn1' strains. 
To test this hypothesis, we used Northern blot analysis to 
compare Pla2s expression in the intestines of B6 and AKR 
mice. Pla2s expression was observed in the small and 
large intestine of AKR mice, where an 800 bp transcript 
was detected after an overnight exposure to autoradiogra- 
phy film (Figure 2). In contrast, no transcript was detected 
in the small or large intestine of B6 mice after a similar 
exposure. However, upon longer exposure, a low level of 
expression was observed in the small and large intestine 
of B6 mice (data not shown). These results indicated that 
Pla2s expression was greatly reduced in the intestines of 
B6 mice compared with AKR mice, consistent with the 
candidacy of the Pla2s gene for the Moml  locus. 
To explore further the candidacy of Pla2s for Morn1, we 
examined Pla2s expression in MA and CAST, two strains 
determined to contain the Morn1' allele (Dietrich et al., 
1993). High levels of the 800 bp transcript were detected 
in the small and large intestines of these strains (Figure 
2A). We next examined six additional strains to determine 
whether the absence of Pla2s expression was unique to 
B6. Northern blot analysis identified three strains, C3H/ 
HeJ (C3H), CBNJ (Figure 2A), and DBN2J (data not 
shown), with high levels of Pla2s expression in the large 
and small intestine. In contrast, four strains, P/J, A/J, C58/ 
J (Figure 2B), and 129/SVJ (data not shown), were identi- 
fied that had greatly reduced levels of Pla2s, similar to the 
expression level observed in B6 mice. Though none of 
these strains have been tested for their Morn1 phenotype, 
we predict hat C3H and CBA/J mice carry a Momlrallele, 
while P/J, N J, C58/J, and 129/SVJ mice carry a Moml  ~ 
allele. Consistent with this prediction, it was recently re- 
ported that 129/SVJ mice carrying a targeted mutation in 
the Apc gene develop high numbers of intestinal adeno- 
mas, indicating that 129/SVJ mice carry the MomP allele 
(Fodde et al., 1994; Laird et al., 1995). The reduced level 
of Pla2s expression observed in Morn1 s strains compared 
with the high level of Pla2s expression observed in Morn1 ~ 
strains is consistent with the hypothesis that the Pla2s 
gene represents the Morn1 locus. 
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Figure 2. Expression of Intestinal Pla2s in Nine Inbred Mouse Strains 
Expression of Pla2s m RNA in the small intestine (SI) and large intestine 
(LI) of nine inbred strains. Total RNA (20 p.g) was subjected to Northern 
blot analysis. The membrane was hybridized to a Pla2s cDNA probe. 
After exposure, the membranes were rehybridized to 18S ribosomal 
RNA to demonstrate he presence of RNA in each lane. Size markers 
are shown to the left. 
(A) Strains that exhibit high levels of Pla2s expression, with B6 mice 
included as a control. 
(B) Strains that exhibit low levels of Pla2s expression, with AKR mice 
included as a control. Strains that expressed high levels of Pla2s con- 
sistently had higher expression levels in the small intestine compared 
with the large intestine. The 2.6 kb transcript isof unknown origin and 
was consistently detected in strains expressing Pla2s. 
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Detection of an RFLP Concordant 
with Pla2s Expression 
The low levels of Pla2s expression observed in B6 mice 
could be the result of a mutation in the promoter region 
resulting in a decreased transcription rate or a mutation 
in the transcribed region resulting in a decreased half-life 
of the Pla2s mRNA. To distinguish between these possibili- 
ties, genomic DNA from B6 and AKR mice was digested 
with several restriction endonucleases to identify RFLPs 
for the Pla2s gene. Southern blot analysis identified three 
enzymes, BamHI, Mspl, and Taql, that revealed RFLPs 
between the B6 and AKR strains (data not shown). Diges- 
tion of genomic DNA with BamHI produced a 9.0 kbfrag- 
ment in the B6 strain and fragments of 2.5 kb and 6.5 kb 
in the AKR strain (Figure 3). To assess whether this RFLP 
was linked to the expression of Pla2s, nine additional in- 
bred strains were analyzed by RFLP analysis. Interest- 
ingly, the six inbred strains expressing high levels of P/a2s 
(AKR, MA, C3H, CBA/J, DBA/2J, and CAST) exhibited the 
2.5 kb and 6.5 kb BamHI fragments, while the five inbred 
strains expressing low levels of Pla2s (B6, A/J, P/J, 129/ 
SvJ, and C58/J) exhibited the 9.0 kb BamHI fragment (Fig- 
ure 3). Thus, there is a 100% concordance between spe- 
cific BamHI RFLPs and Pla2s expression levels. Neither 
the Mspl nor the Taql polymorphism was concordant with 
P/a2s expression (data not shown). These data indicated 
that the level of expression observed in the different strains 
was tightly linked to the BamHI RFLP. The lack of concor- 
dance with other identified RFLPs also suggested that the 
observed expression differences is not the result of a gross 
chromosomal rearrangement. 
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Figure 3. RFLP Analysis of the P/a2s Gene Reveals a BamHI Polymor- 
phism Concordant with Expression Levels 
Genomic DNA (5,0 ~g/lane) from 11 inbred strains was digested with 
BamHl. The DNA was electrophoresed in a 0.8o,~ agarose gel and 
transferred to a Hybond N + filter. Hybridization was carried out under 
high stringency with ~P]dCTP-labeled mouse P/a2s cDNA carrying 
the entire coding sequence. The sizes of the identified restriction frag- 
ments are shown. 
Sequence Analysis of the Murine Pla2s cDNA 
To identify the molecular basis of the Pla2s RFLP detected 
between the AKR and B6 strains, mouse Pla2s cDNA was 
isolated from an ileal cDNA (B6 x C3H)F1 library (Cross- 
man et al., 1994). Screening with a rat Pla2s cDNA probe 
(ishizaki et al., 1989) yielded two positive clones, MPla2s-2 
and MPla2s-6. Both clones were most likely derived from 
the C3H allele, since Pla2s expression is much higher in 
C3H mice than in B6 mice. Both clones contained the 
entire Pla2s open reading frame including the amino- 
terminal signal peptide (Figure 4). Clone MPla2s-6 also 
included a potential polyadenylation s te closely followed 
by a stretch of adenines indicative of a poly(A) ÷ tail. Se- 
quence comparison indicated that the clones were 99% 
identical with the BALB/c Pla2s nucleotide sequence (Mul- 
herkar et al., 1993; GenBank accession number X74266) 
and 86% identical with the rat Pl 2s nucleotide sequence 
(Ishizaki et al., 1989; Komada et al., 1990). 
Identification of an Insertion Mutation 
in Moml" Mice 
Sequence comparisons among the mouse, rat, and hu- 
man PLA2S cDNAs revealed the presence of a conserved 
BamHI site at position 207 (Figure 4) (Ishizaki et al., 1989; 
Kramer et al., 1989). We ascertained whether the BamHI 
site in the open reading frame (at position 207) was poly- 
morphic between Moml r and Morn1 = strains. Reverse 
transcription PCR (RT-PCR) of total RNA from the small 
and large intestines of nine mouse strains (including B6 
and AKR) was performed to determine the conservation 
of the Bam HI site located at position 207 of the Pla2s gene. 
All the strains assayed, regardless of the Pla2s allele, pro- 
duced the expected PCR product of -720 bp (Figure 5). 
In addition to the 720 bp product, the inbred strains exhib- 
iting the 9.0 kb BamHI allele produced a 610 bp PCR 
product (Figure 5). 
Sequence analysis of the 720 bp RT-PCR product from 
AKR intestinal RNA and the 720 bp and 610 bp RT-PCR 
products from B6 intestinal RNA revealed that the Bam HI 
site was present in the AKR product but was absent in 
the B6 products. A single base pair insertion was detected 
in the B6 strain within the BamHI site (Figure 6A). The inser- 
tion of a thymidine residue at this site results in the destruc- 
tion of the BamHI site in the B6 strain and the production of 
the 9.0 kb restriction fragment (see Figure 3). The mutated 
sequence 5'-GGA'F~'_CC-3' is detected in all strains con- 
taining the 9.0 kb BamHI allele and exhibiting reduced 
expression of Pla2s. The insertion results in a frameshift 
mutation that creates a stop codon 13 amino acids down- 
stream in exon 4 (see Figure 4). In contrast, the RT-PCR 
product from the AKR strain contained the BamHI site that 
was observed in both C3H and BALBIc mice (see Figure 
4; Mulherkar et al., 1993). Similarly, the BamHI site was 
detected in all inbred strains possessing the 2.5 kb and 
6.5 kb BamHI fragments, consistent with this site causing 
the polymorphism. 
Sequence analysis of the 610 bp B6 fragment revealed 
the presence of the thymidine insertion at the BamHI site 
located in exon 3. In addition, the 610 bp fragment was 
found to result from exon 3 splicing directly into exon 5, 
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1 CGGCACGAGAGAAACCATACCACCATCCAAGAGAGCT GACAGCATGAAGGTCCTCCTCCTGCTAGCAGCCTCGATCATGGCCTTTGGCTC 90 
M K V L L L L A A S I M A F G S 14 
15 I O V 0 G N I A Q F G g M I R L K T G K R A E L S Y A F Y G 44 
181 ATGCCACTGTGGCCTGGGT CCAAGGATGCCACAGACCGGTGCTGTGTTACTCATGACTGT TGCTACAAGAGCCTGGA 270 
45 C H C G L G K D A T D R C C V T H D C C Y K S L E 74 
B6alt  F P . .~  _G_ _ _C_ _H_ _ R P 
271 GAAAAGTGGATGTGGTACTAAGT TACTGA~TACAAGT/%CTCCCAC~CAAATCACCTGTTCT~l%AACCAC~CTCC TGTCA 3"0 
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B6alt 9_ 2___R_ i_ 2_._V_ R_ 
361 GAAACGGCTGTGTCAGTGCGATAAAGCCGCCGC TGAATGTTTCGCCCGGAACAAGAAAACCTACAGTTTAAAGTACCAGTTCTACCCCAA 450 
105 K R L C Q C D K A A A E C F A R N K K T Y S L K Y Q F Y P N 134 
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451 CATGTT TTGCAAAC-GGAAGAAGCCCAAATGCTGAAAAGAGCCATcTCCT~AAACAcccGGACATGcC-CGTCT~CATCAcAcCTcT~CA 540 
135 M F C K G K K P K C * 164 
631 CACAGGAGTCTTCTGAGTCAGC-CTGACCTTTCCCCACCACTCCACTTCCTTGAATCTGTCTAC TTCCACCT TTC TCTTGGC TCCAACTT 720 
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Figure 4. The Sequence of the Mouse Pla2s 
cDNA 
The nucleotide and predicted amino acid se- 
quences of mouse Pla2s are shown. The paired 
closed boxes above the nucleotide sequence 
denote intron/exon junctions as determined by 
genomic sequencing (data not shown). The sin- 
gle underlined region indicates the signal se- 
quence. The boxed sequence denotes the 
BamHI site mutated in Moml ~ strains; the thy- 
midine insertion is shown within the box. The 
predicted amino acid sequence of wild-type 
Pla2s is shown immediately below the nucleo- 
tide sequence. The two predicted proteins of 
Moml ~ strains are shown from the site of the 
thymidine insertion. The sequence indicated 
by the broken underline and labeled B6alt is 
the predicted peptide derived from the splicing 
of exon 3 into exon 5, thus the gap encom- 
passing exon 4 (see Figure 5). The sequence 
indicated by the broken underline and labeled 
B6 is the truncated product generated from the 
correctly spliced mRNA. 
with the exclusion of exon 4 (Figure 6B). To confirm the 
sequencing results, the 720 bp RT-PCR products from 
both B6 and AKR intestinal RNA were subjected to BamHI 
digestion. The RT-PCR product amplified from AKR intes- 
tinal RNA was digested into two smaller fragments of 
120 bp and 600 bp in length, while both the 720 bp and 
610 bp fragments amplified from B6 mRNA failed to digest 
with BamHI (data not shown). 
The Thymidine Insertion Is Present 
in Genomic DNA 
To rule out posttranscriptional processing as a cause of 
the thymidine insertion in exon 3, we subjected genomic 
DNA from AKR and B6 mice to PCR using primers specific 
for exons 3 and 5 of the Pla2s gene. The resultant 2.2 kb 
products from AKR and B6 were sequenced. The insertion 




Figure 5. RT-PCR Analysis of Intestinal RNA Reveals the Presence 
of Pla2s in All Strains and an Alternatively Spliced Product in Moml ~ 
Strains 
RT-PCR products derived from total RNA isolated from the small intes- 
tine of nine inbred strains listed at the top. PCR products were electro- 
phoresed on 2.0% agarose gels and visualized with ethidium bromide. 
The primers used for PCR were 5'-GAAACCATACCACCATCCAA-3' 
and 5'-CCAGGACTCTCTTAGGTACG-3', which amplified nucleotides 
11-747 of the murine Pla2s cDNA (Figure 4). The size marker is the 
1 kb ladder (GIBCO-BRL, Gaithersburg, Maryland). The negative con- 
trol (neg control) is made of the the same components as all other 
lanes except that no RTase was added. 
in the B6 product, while a normal BamHI site was observed 
in the AKR product (Figure 6C). These results demonstrate 
that the insertion of a thymidine at the BamHI site is re- 
sponsible for the RFLP identified by Southern blot analy- 
sis. Moreover, these results suggest that this mutation is 
responsible for the Moml  ~ phenotype. 
Discussion 
Morn1 and Pla2s 
Genetic modifiers of cancer have long been predicted to 
exist. The generation of mouse models of human cancer 
coupled with QTL analysis have enabled the identification 
of these modifier loci. Moml  was shown to contribute 
50% of the genetic variance responsible for intestinal 
neoplasia in Min mice (Dietrich et al., 1993). The results 
described here suggest that allelic variants of the Pla2s 
gene are responsible for Moml  phenotypes. Genetic and 
molecular analysis demonstrated that Pla2s maps to the 
same chromosomal region as Moml  and that Moml  s 
strains express a mutated form of Pla2s. We also deter- 
mined the expression pattern of Pla2s in seven strains of 
mice not analyzed for their Moml  allele and found that 
they fell into two distinct classes: the first class was like 
the wild-type AKR pattern of expression, and the second 
class was like the mutant B6 pattern. 
Probability theory can provide the l ikelihood that the two 
alleles of Pla2s would segregate with Moml  genotypes 
by chance. The B6 and 129/SVJ strains have the Moml  ~ 
allele and the Pla2s mutation, whereas the AKR, MA, and 
CAST strains have the Moml  r allele and a wild-type Pla2s 
gene. We have also found that the P/J strain carries the 
Moml  ~ allele, based on the average number of tumors 
(34.8) present in F1 hybrids from a cross between (P/J x 
B6-ApcMi"l+) mice (M. M., L. D. S., and A. M. B., unpub- 
lished data). Six additional strains (A/J, CBA/J, C3H, 
C58/J, DBA/2J, and M. spretus) have been characterized 
for their Pla2s allele, but not their Moml  genotype (Figure 
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Figure 6. Identification of the Pla2s Polymorphism 
(A) cDNA sequence surrounding the polymorphic BamHI derived from B6, MA, and AKR 
intestinal RNA. The thymidine insertion in the B6 strain is indicated bythe arrow. RT-PCR 
products were purified from a 2.0o/0 low melt agarose gel and sequenced. The primer used 
for sequencing the polymorphic region was 5'-GCGCAGTI-FGGGGAAAT-3', corresponding 
to base pairs 113-130 of the Pla2s cDNA. 
(B) Sequence of the novel RT-PCR product detected in B6 intestinal RNA. The nucleotide 
sequence surrounding the novel junction between exon 3 a d exon 5 identified in B6 mice 
is shown. Exons 3 and 5 are denoted by brackets. 
(C) The presence of the BamHI polymorphism is confirmed in genomic DNA. PCR products 
were generated from genomic DNA from B6 and AKR mice. Genomic DNA (100 ng) was 
amplified with primers 5'-GAGAGCTGACAGCATGAAGG-3' and 5'-CCGTTTCTGACAG- 
GAGTICTGGTT-3', corresponding to base pairs 31 and 368 of the Pla2s cDNA. Sequencing 
was performed using the primer 5'-GCGCAGTTTGGGGAAAT-3', corresponding tobase pairs 
113-130 of the Pla2s cDNA. The thymidine insertion in the B6 strain is indicated by the arrow. 
reflects the population frequency of the mutation in all 
mouse strains, the frequency that by chance three Morn 1 ~ 
strains would carry the mutant Pla2s allele and three 
Moml '  strains would carry the wild-type Pla2s allele is (6/ 
12) 8 or 1.56%. Thus, the odds are 63 to 1 that the associa- 
tion between Morn1 genotype and Pla2s allele is not a 
random event, but rather represents a causal relationship. 
Southern blot analysis revealed that the Pla2s expres- 
sion differences detected between the inbred strains was 
concordant with a BamHI polymorphism. Cloning and se- 
quencing of the Pla2s cDNA from both Momlrand  Morn1 ~ 
strains revealed that the BamHI polymorphism mapped 
to the middle of exon 3. The polymorphism results from 
the insertion of a single thymidine residue in the BamHI 
site that causes a frameshift mutation resulting in a stop 
codon in exon 4 (Figure 4). Analysis of frameshift and 
nonsense mutations has revealed that these mutations 
often result in decreased steady-state levels of mRNA (Bel- 
grader and Maquat, 1994), consistent with the dramati- 
cally lower steady-state levels of Pla2s mRNA (Figures 2A 
and 2B). In addition, analysis of RT-PCR products re- 
vealed that a second transcript is present in intestinal RNA 
isolated from mice carrying the Moml  ~ allele (Figure 5). 
This second transcript results from the splicing of exon 3 
into exon 5, skipping exon 4 (where the nonsense codon 
occurs) (Figures 4 and 613). This alternative splicing still 
results in a +1 shift in the open reading frame, yielding a 
novel carboxyl terminus. The appearance of an alterna- 
tively spliced Pla2s transcript in B6 mice is consistent with 
reports that identified exon skipping due to the presence 
of nonsense codons within the deleted exon (Dietz et al., 
1993; Belgrader and Maquat, 1994). 
In Moml  s strains, if the two alternative transcripts are 
translated, the resulting proteins would most likely be non- 
functional. The predicted product of the normally spliced 
transcript would result in the addition of a novel 13 amino 
acids followed by a stop codon (Figure 4, B6). This trun- 
cated protein would be missing 12 of the 14 conserved 
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cysteine residues critical for maintaining secondary struc- 
ture and stability. The predicted product derived from the 
alternatively spliced form would contain a novel 37 amino 
acid carboxyl terminus (Figure 4, B6alt). This form would 
also lack enzymatic activity owing to loss of the structural 
integrity of the Pla2s protein. 
These results indicate that the increased tumor suscep- 
tibility in Moml  s strains is either due to the expression of 
abnormal Pla2s protein(s) or due to the lack of wild-type 
Pla2s enzyme activity. Since the resistance to tumor for- 
mation observed in hybrid F1 mice generated from a cross 
between Moml  ~ and Morn1 ~ mice is dominant, the most 
likely hypothesis is that the presence of wild-type Pla2s 
enzyme activity confers resistance to multiple adenoma 
formation, while the truncated product(s) has no effect on 
tumor formation. 
Pla2s and Inflammation 
There is as yet no consensus as to how many Pla2s-related 
genes exist in the mammalian genome. Southern blot hy- 
bridization suggests that there is a single Pla2s locus in 
both human and rat genomes (Kramer et al., 1989; Ko- 
mada et al., 1990). However, Johnson et al. (1990) identi- 
fied two distinct sequences related to the human PLA2S 
gene. Furthermore, Chen et al. (1993) have sequenced a 
novel Pla2s gene expressed mainly in heart. These results 
suggest that there exists multiple forms of Pla2s in the 
mammalian genome. Pla2s has been widely implicated in 
being instrumental in the inflammatory process (reviewed 
by Pruzanski and Vadas, 1991; Mukherjee et al., 1992). 
However, our results indicate that several inbred strains 
lack this enzyme activity (B6, A/J, C58/J, P/J, and 129/ 
SvJ). To our knowledge, no data have been presented 
that indicate that Morn1 ~ mice have an altered or impaired 
inflammatory response. A comparison of the inflammatory 
process between Morn1 ~ and Morn1 r strains would further 
elucidate the role of Pla2s in inflammation and arthritis. 
Nonsteroidal Anti-Inflammatory Drugs 
and Colon Cancer 
Pla2s is one of several enzymes involved in generating 
arachidonic acid and lysophosphatidic acid. Arachidonic 
acid is the rate-limiting substrate for the generation of pros- 
taglandins and leukotrienes (reviewed by Glaser et al., 
1993). Although previous studies have suggested the po- 
tential roles of phospholipase C and prostaglandins in the 
development of intestinal adenomas, no evidence impli- 
cating Pla2s has been found (Rao et al., 1995). In addition, 
numerous studies in both human and rodent have demon- 
strated that nonsteroidal anti-inflammatory drugs (NSAIDs) 
confer a protective effect in the generation of colon adeno- 
mas. The mechanism of action of NSAIDs such as Sulindac 
is presumed to be by inhibiting cyclooxygenase, resulting 
in a decrease in prostaglandin production (reviewed by 
Marnett 1992; Thun, 1994). Studies have determined that 
Sulindac significantly decreased the levels of prostaglan- 
din E2 in colonic mucosa and tumors (Rao et al., 1995). 
Thus, it has been hypothesized that the decrease of spe- 
cific prostaglandins contributes to tumor protection and 
polyp regression. Since our results suggest that increased 
levels of Pla2s can also yield a protective ffect, it suggests 
that Sulindac and other NSAIDs might ameliorate polyp 
formation by a more complicated mechanism. 
The Role of Pla2s in Modifying Tumor Susceptibility 
One potential hypothesis for the mode of action of Pla2s 
might be in its role in lipid homeostasis. Though it is be- 
lieved that pancreatic type I Pla2s is responsible for the 
digestion of fatty acids, the presence of high quantities of 
type II Pla2s in the intestine is suggestive of a role in the 
digestion of dietary fats. There is a strong positive correla- 
tion between fatty acid intake and an increased suscepti- 
bility to colon cancer (reviewed by Reddy, 1993). Thus, 
dietary lipids might interact with the intestinal villi to stimu- 
late the formation of aberrant crypts. Therefore, the pres- 
ence of high levels of Pla2s in the intestine could provide 
a protective ffect by inactivating harmful effects of dietary 
fatty acids. Alternatively, Pla2s may be important for main- 
taining normal intestinal flora; different ypes of dietary fat 
are associated with alteration of the normal intestinal flora. 
Diets high in saturated fatty acid are associated with in- 
creased amounts of the anaerobic bacteria, Bacteroides 
(Pence, 1985). It has recently been demonstrated that puri- 
fied type II Pla2s from mouse intestines possesses potent 
bactericidal activity (Harwig et al., 1995). Since Pla2s is 
secreted from Paneth cells and these cells secrete many 
bactericidal proteins, it is not surprising that Pla2s has a 
role in microbial defense mechanisms. Thus, Moml '  strains 
have high levels of Pla2s in their intestinal lumen that helps 
protect or control intestinal flora (or both), while Moml  ~ 
strains lack sufficient levels of Pla2s to affect bactericidal 
activity. Bacteroides and other anaerobic bacteria have 
been proposed to produce toxins or convert bile salts to 
carcinogenic products (van Tassell et al., 1990; Rumney 
et al., 1993). Thus, the lack of Pla2s in the intestine of B6 
mice allows for the proliferation of certain types of bacteria 
that produce carcinogenic products that facilitate polyp 
formation and transformation. 
Alternatively, murine intestinal Pla2s was independently 
identified as enhancing factor (Deo et al., 1983; Mulherkar 
et al., 1993). Enhancing factor was isolated as a low molec- 
ular mass heat and acid stable polypeptide that enhanced 
the binding of epidermal growth factor to cells. Pla2s was 
also found to induce DNA synthesis and proliferation inde- 
pendent of arachidonate products (Kurizaki et al., 1992). 
Thus, the presence of high levels of Pla2s in intestinal 
crypts might provide an environment that would inhibit he 
formation of transformed crypts owing to the enhanced 
accessibility of growth factors. 
A final potential mechanism of Pla2s action is its role 
in maintenance of membrane asymmetry. Pla2s activity 
requires millimolar concentrations of Ca 2÷, suggesting that 
Pla2s must be released into the extracellular environment 
to become fully active. In addition, the specificity of Pla2s 
in the microenvironment is mediated by membrane asym- 
metry (Kudo et al., 1993); specifically, Pla2s has a prefer- 
ence for the head group of anionic phospholipids (i.e., 
phosphatidylserine) and phosphatidylethanolamine lo- 
cated on the external membrane. Normal colonic epithe- 
lium has phosphatidylcholine on its external leaflet, a 
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phospholipid that is a low affinity substrate of Pla2s (Four- 
cade et al., 1995). Taken together, these data suggest 
that Pla2s does not catalytically attack the membrane 
phospholipids of normal intestinal epithelium. In contrast, 
bacterial cell membranes, comprised mostly of phosphati- 
dylglycerol, are a prime target for Pla2s action, hence its 
bactericidal properties (see above). However, loss of the 
membrane asymmetry in intestinal epithelium could lead 
to increased accessibility of cell membrane phospholipids 
to Pla2s enzymatic activity. Colon carcinoma cells have 
elevated levels of phosphatidylserine on their external 
leaflet, providing a suitable target for Pla2s digestion (Ut- 
sugi et al., 1991). If the membrane phospholipid shift oc- 
curs at an early point in the transformation of intestinal 
epithelium, then high levels of Pla2s in the intestine may 
provide a protective function by eliminating aberrant crypt 
cells while low levels may allow unbridled growth of trans- 
formed cells. 
Prospectus 
Pla2s represents a novel class of genes that influence 
tumor susceptibility. Several mechanisms to explain how 
Pla2s activity could contribute to tumor resistance have 
been proposed. Regardless of the mechanism, it is proba- 
ble that the mode of protection is noncell autonomous, 
since Pla2s is most active in the intestinal umen and not 
within the cell. Recently, Laird et al. (1995) identified an- 
other modifier of murine intestinal cancer that is intrinsic 
to the transformed cell. This modifier confers tumor resis- 
tance by causing DNA hypomethylation (Laird et al., 1995). 
The identification of this cell-autonomous modifier was ac- 
complished through the use of gene targeting and drug 
treatment in mice. The proposed models for Pla2s action 
are testable through the use of mouse mutants and 
through experimental manipulation of the diet and drug 
treatment of Morn1 s and Momlrstrains. The ultimate proof 
of Pla2s identity with Moml  will be shown by expressing 
a wild-type copy of the Pla2s gene within the microenviron- 
ment of the intestinal crypts in Morn1 s strains and demon- 
strating a reduction in the number of adenomas or by tar- 
geted ablation of the Pla2s gene in Morn1' strains. 
The human homolog of Pla2s has been localized to chro- 
mosome lp35 (Johnson et al., 1990), a region that exhibits 
loss of heterozygosity in a variety of neoplasms (Mar- 
tinsson et al., 1989; Leister et al., 1990). However, owing 
to the proposed noncell-autonomous mode of action for 
Pla2s, it is unclear as to how loss of PLA2S in tumor cells 
would contribute to neoplasia. Thus, one would not expect 
to find loss of heterozygosity at the MOM1 locus in human 
or murine tumors. 
The identification of Pla2s as a candidate gene for the 
Morn1 locus has important implications in human cancer. 
One possibility of PLA2S involvement may be reflected by 
the variable number of adenomas identified among FAP 
family members inheriting the same APC mutation. This 
variation in tumor burden could be attributable to the seg- 
regation of different PLA2S alleles. In addition, population 
surveys would be useful for both determining the extent 
of PLA2S allelic variation as well as for identifying individu- 
als at risk for developing intestinal cancer. Finally, the 
identification of Pla2s as a candidate for a major modifier 
of intestinal polyp formation may provide a missing link 




The chromosomal location of Pla2s was determined by interspecific 
backcrossanalysisof[(AEJ/Gn-abpM/abp M x Musspretus)F1 x AEJ/ 
Gn-a bpH/a b/P] mica (Argeson et al., 1995). Additional inbred strains 
were purchased from The Jackson Laboratory (Bar Harbor, ME). 
Probes 
Probes used to map the mouse Pla2s gene and screen murine cDNA 
libraries were derived from a 758 bp rat cDNA fragment cloned into 
the EcoRI site of a pGEM vector. The pGEM vector containing the rat 
Pla2s gene was a gift from Dr. J. Ishizaki (Ishizaki et al., 1989; Shionogi 
Research Laboratories, Osaka, Japan). A 456 bp fragment of the rat 
Pla2s coding region was amplified by the PCR using primers 5'-ATG- 
AAGGTCCTCCTG'R'G-3' and 5'-CAGAGAGTGTCTT'I-I'CAGC-3'. The 
probe was radiolabeled with [a-=P]dCTP using a random prime kit 
(Boehringer Mannheim, Indianapolis, IN). The Pla2s probe hybridized 
to a 9.0 kb BamHI fragment in the M. spretus parental strain and a 
2.5 kb BamHI fragment in the AEJ/Gn parental strain. 
cDNA Cloning 
Murine Pla2s clones (MPla2sl-6) were isolated from a (B6 x C3H)F1 
ileal cDNA library made from the terminal 3.0 cM of the small intestine 
(Crossman et al., 1994); the library was a gift from Dr. J. Gordon (Wash- 
ington University School of Medicine, St. Louis, MO). Clones were 
isolated by standard techniques (Sambrook et al., 1989). A 780 bp 
fragment of the clone was PCR amplified using T3 and T7 primers. 
PCR products were purified by electrophoresis on a low melt agarose 
gel and radiolabeled as above. 
SSLP Analysis 
DNA primers for SSLP analyses were made (Ma et al., 1993). Genomic 
DNA isolation and agarosa gel electrophoresis were as described pre- 
viously (Siracusa et al,, 1987). Prim ers and fragment sizes for D4Mitl 3, 
D4Mit16, and D4Mit148 were as described previously (Dietrich et al., 
1992). The resulting D4Mit148 fragments were visualized by EtBr stain- 
ing of 3% agarose gels, while 10% and 5o/0 polyacrylamide gels were 
used for D4Mit13 and D4Mit16, respectively. 
DNA Isolation and Southern Blot Analysis 
Genomic DNAs were isolated from tail biopsies as described pre- 
viously (Siracusa et al., 1987). DNA (5.0 p.g) was digested with the 
appropriate restriction endonucleases according to the directions of 
the supplier, fractionated on 0.8% agarose gels, and transferred to 
Hybond N ÷ nylon membranes (Argeson et al., 1995), Hybridization to 
[o-~P]dCTP-labeled probes was as described previously (Church and 
Gilbert, 1984). Membranes were washed in 1 x SSCP, 0.1o/0 SDS at 
65°C and exposed to autoradiography film at -70°C. 
RNA Isolation and Northern Blot Analysis 
Total mouse RNA was isolated as described previously (Ma et al., 
1993). Total RNA (20 p,g) was size-fractionated on 1.0% formalde- 
hyde-agarose gels (Sambrook et al., 1989). Northern blots were trans- 
ferred and hybridized as described above. 
RT-PCR and Sequence Analysis 
First-strand cDNA was synthesized from 1.0 p.g of total RNA using 
oligo(dT)~5 and MoMLV RTase (Sambrook et al., 1989). PCR was per- 
formed, as described above, using primers specific for murins Pla2s. 
Double-stranded cDNA products were purified using QIAquick PCR 
purification columns (Qiagen, Chatworth, CA), dried, and resuspended 
in 10 p~l of H20. 
Long-range PCR of genomic DNA fragments was performed using 
the KlenTaq I and polymerasa II kit (Ab Peptides, St. Louis, MO). PCR 
amplification of genomic DNA (100 ng) was 25 cycles at 95°C for 5 
s, 65°C for 30 s, and 68°C for 7 rain. PCR products were purified as 
Secretory Phospholipase A2 and Intestinal Neoplasia 
965 
described above. Sequencing reactions of the PCR products were 
performed using dideoxy terminator eaction chemistry and analyzed 
on an Applied Biosystems model 373 DNA sequencer. 
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